製藥公司展望：∼2014年 是由出版商Datamonitor在2009年12月所出版的。
這份英文市場調查報告書包含121 pages 價格從美金7600起跳。
處方藥之銷售額從2008年至2014年為止，CAGR被預測會擴大1.2%，但仍低於2002至2008年間的9.3%。
本研究報告彙整主要製藥公司2014年為止之銷售展望、未來新產品之上市動向、具發展潛力之治療領域等議題。報告內容摘記如下。
序論
研究摘要
大型製藥公司2014年為止之展望
- 主要調査結果
- 2014年為止大型製藥公司之概況
- 大型製藥公司分析
- 上市／主力產品／到期專利分析
- 治療領域分析
- 藥物分子種類
中型製藥公司2014年為止之展望
- 主要調査結果
- 2014年為止中型製藥公司之概況
- 中型製藥公司分析
- 上市／主力產品／到期專利分析
- 治療領域分析
- 藥物分子種類
生技公司2014年為止之展望
- 主要調査結果
- 2014年為止生技公司之概況
- 生技公司分析
- 上市／主力產品／到期專利分析
- 治療領域分析
- 藥物分子種類
日本製藥公司2014年為止之展望
- 主要調査結果
- 2014年為止日本製藥公司之概況
- 日本製藥公司分析
- 上市／主力產品／到期專利分析
- 治療領域分析
- 藥物分子種類
附錄
圖表
Abstract
Introduction
PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of
1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this
falling rate is the much-discussed genericization of small molecule products.
However, not all sectors are equally exposed, prompting a shake-up of the
industry and an increasing pursuit of cost savings to sustain operating profit
growth rates.
Scope of this research
- Analysis of the sales outlook for the PharmaVitae universe of leading
prescription pharma companies to 2014
- Assessment of the impact of future launches and patent expiries on sales
growth compared to historical trends
- Segmentation of the market by therapy area and molecule type to assess
high- and low-growth sectors of the industry
- Assessment of the impact of cost-cutting on operating profit growth in an
environment of low and sometimes negative sales growth
Research and analysis highlights
The increasing assault of generics on leading pharma players' staple diet of
small molecule products will prompt a shake-up of the industry. Companies'
success will be heavily linked to their exposure to this generic threat, with
biologics and niche players enjoying the greatest insulation and therefore
often the highest growth.
Many companies not in these hot sectors of the industry will be compelled to
pursue cost-cutting to maintain previous levels of operating profit growth and
some may resort to M&A activity to bolster sales performance and/or
strategically realign themselves.
However, recourse to M&A should not be surprising when looked at in the
historical context, as this has already acted as the PharmaVitae universe' s
primary growth driver in the period between 2002 and 2008, accounting for a
greater proportion of growth than internal R&D operations.
Key reasons to purchase this research
- Gain a true understanding of the threats facing the pharmaceutical
industry' s sales performance and which sectors will be most heavily impacted
- Assess the effectiveness of cost-cutting programs on operating profit
performance in a period of low sales growth
- Evaluate the impact of M&A on companies' historical performance and see
how low top-line sales growth could prompt a further wave of consolidation
Table of Contents
INTRODUCTION
EXECUTIVE SUMMARY
- Key findings
- Overview of the PharmaVitae Universe outlook to 2014
- Introduction to the PharmaVitae Universe
- Industry coverage of the PharmaVitae Universe
- The PharmaVitae peer sets
- Strategic overview of the PharmaVitae Universe to 2014
- The company outlook to 2014
- PharmaVitae Universe launch/core/expiry analysis
- PharmaVitae Universe molecule type analysis
- PharmaVitae Universe M&A analysis
THE BIG PHARMA OUTLOOK TO 2014
- Key findings
- Overview of Big Pharma to 2014
- Big Pharma prescription pharma sales performance, 2002 - 14
- Big Pharma landscape, 2008 - 14
- Big Pharma company analysis
- Big Pharma company sales, 2008
- Big Pharma company sales outlook, 2008 - 14
- Big Pharma launch/core/expiry analysis
- Big Pharma therapy area analysis
- Big Pharma molecule type analysis
THE MID PHARMA OUTLOOK TO 2014
- Key findings
- Overview of Mid Pharma to 2014
- Mid Pharma prescription pharma sales performance, 2002 - 14
- Mid Pharma landscape, 2008 - 14
- Mid Pharma company analysis
- Mid Pharma launch/core/expiry analysis
- Mid Pharma therapy area analysis
- Mid Pharma molecule type analysis
THE BIOTECH OUTLOOK TO 2014KEY FINDINGS
- Overview of Biotech to 2014
- Biotech prescription pharma sales performance, 2002 - 14
- Biotech landscape, 2008 - 14
- Biotech company analysis
- Biotech launch/core/expiry analysis
- Biotech therapy area analysis
- Biotech molecule type analysis
THE JAPAN PHARMA OUTLOOK TO 2014
- Key findings
- Overview of Japan Pharma to 2014
- Japan Pharma prescription sales performance, 2002 - 14
- Japan Pharma landscape, 2008 - 14
- Japan Pharma company analysis
- Japan Pharma launch/core/expiry analysis
- Japan Pharma therapy area analysis
- Japan Pharma molecule type analysis
APPENDIX
- Abbreviations
- Exchange rates
TABLES
- Table: Strategic overview of the PharmaVitae Universe, 2008 - 14
- Table: PharmaVitae Universe overview by peer set, 2008 - 14
- Table: Launch/core/expiry analysis (percentage of 2002 sales), 2002 - 08
- Table: Launch/core/expiry analysis (percentage of 2008 sales), 2008 - 14
- Table: Big Pharma peer set overview, 2008 - 14
- Table: Big Pharma launch/core/expiry portfolios, 2008 - 14
- Table: Mid Pharma peer set overview, 2008 - 14
- Table: Mid Pharma launch/core/expiry portfolios, 2008 - 14
- Table: Biotech peer set overview, 2008 - 14
- Table: Biotech launch/core/expiry portfolios, 2008 - 14
- Table: Japan Pharma peer set overview, 2008 - 14
- Table: Japan Pharma launch/core/expiry portfolios, 2008 - 14
- Table: Exchange rates, 2009
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: PharmaVitae Universe prescription pharma sales ($bn) and
year-on-year growth rate (%), 2002 - 14
- Figure: PharmaVitae Universe prescription pharmaceutical sales ($bn) by
company, 2008
- Figure: PharmaVitae Universe prescription pharma sales CAGR (%) by
company, 2008 - 14
- Figure: PharmaVitae Universe prescription pharma sales ($bn) by company,
2014
- Figure: PharmaVitae Universe launch/core/expiry analysis, change in sales
($bn), 2002 - 08 and 2008 - 14
- Figure: PharmaVitae Universe launch/core/expiry analysis, change in sales
(% 2008) by peer set, 2008 - 14
- Figure: PharmaVitae Universe launch/core/expiry analysis, change in sales
(% 2008) by company, 2008 - 14
- Figure: PharmaVitae Universe prescription pharma sales ($bn) by molecule
type, 2002 - 14
- Figure: PharmaVitae Universe prescription pharma sales growth ($bn) by
molecule type, 2008 - 14
- Figure: PharmaVitae Universe company-by-company prescription pharma sales
growth ($m) by molecule type, 2008 - 14
- Figure: PharmaVitae Universe prescription pharma sales growth ($bn) by
source, 2002 - 08
- Figure: Big Pharma peer set prescription pharma sales and growth rate,
2002 - 14
- Figure: Big Pharma peer set landscape, 2008 - 14
- Figure: Big Pharma peer set companies, prescription pharma sales ($m), 2008
- Figure: Big Pharma peer set companies, prescription pharma sales CAGR (%),
2008 - 14
- Figure: Big Pharma peer set companies, prescription pharma sales ($bn),
2008 - 14
- Figure: Big Pharma peer set companies, prescription pharma sales ($m), 2014
- Figure: Big Pharma peer set growth by source of product ($m), 2002 - 08
- Figure: Big Pharma peer set launch/core/expiry, 2002 - 14
- Figure: Big Pharma companies launch/core/expiry ($bn), 2008 - 14
- Figure: Big Pharma companies launch/core/expiry as % of 2008 prescription
pharma sales, 2008 - 14
- Figure: Big Pharma peer set, therapy area focus, 2002 - 14
- Figure: Big Pharma company sales by therapy area ($m), 2008
- Figure: Big Pharma company sales by therapy area ($m), 2014
- Figure: Big Pharma peer set, molecule type focus, 2002 - 14
- Figure: Big Pharma peer set growth by molecule type, 2008 - 14
- Figure: Big Pharma companies molecule type focus (% prescription pharma
sales), 2008
- Figure: Big Pharma companies, growth by molecule type, 2008 - 14
- Figure: Big Pharma companies molecule type focus (% prescription pharma
sales), 2014
- Figure: Mid Pharma peer set prescription pharma sales and growth rate,
2002 - 14
- Figure: Mid Pharma peer set landscape, 2008 - 14
- Figure: Mid Pharma peer set companies, prescription pharma sales ($m), 2008
- Figure: Mid Pharma peer set companies, prescription pharma sales CAGR (%),
2008 - 14
- Figure: Mid Pharma peer set companies, prescription pharma sales ($bn),
2008 - 14
- Figure: Mid Pharma peer set companies, prescription pharma sales ($m), 2014
- Figure: Mid Pharma peer set growth by source of product ($m), 2002 - 08
- Figure: Mid Pharma peer set launch/core/expiry, 2002 - 14
- Figure: Mid Pharma companies launch/core/expiry ($bn), 2008 - 14
- Figure: Mid Pharma companies launch/core/expiry (percentage of 2008
Prescription pharma sales), 2008 - 14
- Figure: Mid Pharma peer set, therapy area focus, 2002 - 14
- Figure: Mid Pharma company sales by therapy area ($m), 2008
- Figure: Mid Pharma company sales by therapy area ($m), 2014
- Figure: Mid Pharma peer set, molecule type focus, 2002 - 14
- Figure: Mid Pharma peer set growth by molecule type, 2008 - 14
- Figure: Mid Pharma companies molecule type focus (% prescription pharma
sales), 2008
- Figure: Mid Pharma companies, growth by molecule type, 2008 - 14
- Figure: Mid Pharma companies molecule type focus (% prescription pharma
sales), 2014
- Figure: Biotech peer set Prescription pharma sales and growth rate, 2002 -
14
- Figure: Biotech peer set landscape, 2008 - 14
- Figure: Biotech peer set companies, prescription pharma sales ($m), 2008
- Figure: Biotech peer set companies, prescription pharma sales CAGR (%),
2008 - 14
- Figure: Biotech peer set companies, prescription pharma sales ($bn), 2008
- 14
- Figure: Biotech peer set companies, prescription pharma sales ($m), 2014
- Figure: Biotech peer set growth by source of product ($m), 2002 - 08
- Figure: Biotech peer set launch/core/expiry, ($bn), 2002 - 14
- Figure: Biotech companies launch/core/expiry ($bn), 2008 - 14
- Figure: Biotech companies launch/core/expiry (percentage of 2008
prescription pharma sales), 2008 - 14
- Figure: Biotech peer set, therapy area focus, 2002 - 14
- Figure: Biotech company sales by therapy area ($m), 2008
- Figure: Biotech company sales by therapy area ($m), 2014
- Figure: Biotech peer set, molecule type focus, 2002 - 14
- Figure: Biotech peer set growth by molecule type, ($bn), 2008 - 14
- Figure: Biotech companies molecule type focus (% prescription pharma
sales), 2008
- Figure: Biotech companies, growth by molecule type, ($m), 2008 - 14
- Figure: Biotech companies molecule type focus (% prescription pharma
sales), 2014
- Figure: Japan Pharma peer set prescription pharma sales and growth rate,
2002 - 14
- Figure: Japan Pharma peer set landscape, 2008 - 14
- Figure: Japan Pharma peer set companies, prescription pharma sales ($m),
2008
- Figure: Japan Pharma peer set companies, prescription pharma sales CAGR
(%), 2008 - 14
- Figure: Japan Pharma peer set companies, prescription pharma sales ($bn),
2008 - 14
- Figure: Japan Pharma peer set companies, prescription pharma sales ($m),
2014
- Figure: Japan Pharma peer set growth by source of product ($m), 2002 - 08
- Figure: Japan Pharma peer set launch/core/expiry, ($bn), 2002 - 14
- Figure: Japan Pharma companies launch/core/expiry ($bn), 2008 - 14
- Figure: Japan Pharma companies launch/core/expiry (percentage of 2008
prescription pharma sales), 2008 - 14
- Figure: Japan Pharma peer set, therapy area focus, 2002 - 14
- Figure: Japan Pharma company sales by therapy area ($m), 2008
- Figure: Japan Pharma company sales by therapy area ($m), 2014
- Figure: Japan Pharma peer set, molecule type focus, 2002 - 14
- Figure: Japan Pharma peer set growth by molecule type, ($m), 2008 - 14
- Figure: Japan Pharma companies molecule type focus (% prescription pharma
sales), 2008
- Figure: Japan Pharma companies, growth by molecule type, ($m), 2008 - 14
- Figure: Japan Pharma companies molecule type focus (% prescription pharma
sales), 2014
|
